Bain Capital, Cinven eye $4.7B deal for Lonza unit
February 10, 2021
Share:
Bain Capital and Cinven have agreed to acquire Lonza Specialty Ingredients from Swiss biotech giant Lonza in a deal that values the unit at 4.2 billion Swiss francs (about $4.7 billion), including debt. Based in Basel, Switzerland, LSI makes ingredients for disinfectants, preservatives, sanitizers and a variety of other uses.